# PE 22-28

> A short spadin-derived peptide that blocks the TREK-1 potassium channel, studied as a fast-acting antidepressant and neuroprotective tool.

- Also known as: PE22-28, spadin analog
- Class: Cognitive
- FDA approved: No
- Canonical page: https://americanpeptide.com/catalog/pe-22-28

## Overview

PE 22-28 is a seven-residue peptide derived from spadin, the natural fragment of the sortilin propeptide that blocks the TREK-1 (TWIK-related potassium) channel. TREK-1 blockade is studied as a mechanism for rapid antidepressant action and for neuroprotection, and PE 22-28 was developed as a shortened, more stable spadin analog to probe that pathway. It is a preclinical research peptide with no human data and no approval.

Spadin was identified as an endogenous peptide that blocks TREK-1, a potassium channel whose activity restrains serotonergic signaling. Blocking it produced fast antidepressant-like effects in mice, which made the pathway interesting as an alternative to monoamine-reuptake drugs. PE 22-28 is a short, optimized fragment of spadin designed to keep that TREK-1 activity in a more stable, drug-like peptide.

Research on PE 22-28 spans antidepressant models and, separately, neuroprotection in ischemic (stroke) models where TREK-1 modulation is relevant. The work is preclinical; there is no clinical trial, no human safety data, and no approval. This page is a research and educational reference.

## Mechanism

Blockade of the TREK-1 background potassium channel, which modulates serotonergic neuron excitability; TREK-1 inhibition is associated with antidepressant-like effects and neuroprotection in animal models.

## Research areas

Studied in: Depression models, TREK-1 channel pharmacology, Neuroprotection (stroke models).

Guides on this site:

- [Cognition & Neuroprotection](https://americanpeptide.com/research-areas/cognition-neuroprotection): Nootropic and neurotrophic peptides studied for cognition and recovery.

## Key research

- TREK-1 blocker — a spadin-derived peptide that inhibits the TREK-1 potassium channel.
- Fast antidepressant mechanism — TREK-1 blockade produces rapid antidepressant-like effects in animal models.
- Neuroprotection — studied in ischemic/stroke models alongside its mood effects.
- Preclinical — no human data; not FDA-approved.

## Storage, handling & synthesis

**Storage.** Store lyophilized, frozen, and protected from light; refrigerate reconstituted peptide and use within a short window. A short peptide in solution degrades faster than its lyophilized form.

**Handling.** Reconstitute gently without vortexing. With a seven-residue sequence, confirm identity by mass spectrometry — short peptides are easy to make incorrectly and easy to mislabel.

**Synthesis.** A short linear heptapeptide, straightforward to make by solid-phase synthesis. Purity is governed by removing deletion sequences over a short chain; the harder question is identity — a 7-mer is easy to synthesize and easy to mislabel, so mass spectrometry against the stated sequence is the meaningful check.

## FAQs

### What is PE 22-28?

A short peptide derived from spadin that blocks the TREK-1 potassium channel, studied as a fast-acting antidepressant and neuroprotective agent in preclinical models.

### How does it relate to spadin?

It is a shortened, stabilized fragment of spadin designed to retain spadin’s TREK-1-blocking activity in a more drug-like peptide.

### Is there human evidence?

No — the research is in animal models. There is no clinical trial or human safety data.

### Is it approved?

No. This page is a research and educational reference, not medical advice.

## Latest research

Recent trials and publications mentioning PE 22-28, pulled automatically from ClinicalTrials.gov and PubMed (unfiltered search results, refreshed daily).

### Recent trials

- [Clinical Trial of GenSci136 in Patients With Myasthenia Gravis](https://clinicaltrials.gov/study/NCT07936084) — NOT_YET_RECRUITING · PHASE1, PHASE2 · NCT07936084
- [Trial in Non-cystic Fibrosis Bronchiectasis Patients With Chronic Lung Infections Treated With Colistimethate Sodium.](https://clinicaltrials.gov/study/NCT03460704) — TERMINATED · PHASE3 · NCT03460704
- [Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)](https://clinicaltrials.gov/study/NCT04562766) — COMPLETED · PHASE3 · NCT04562766
- [Personalized Care for Prenatal Stress Reduction & Prevention of Preterm Birth (PTB) Disparities](https://clinicaltrials.gov/study/NCT06915428) — NOT_YET_RECRUITING · NA · NCT06915428
- [SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM](https://clinicaltrials.gov/study/NCT05405166) — ACTIVE_NOT_RECRUITING · PHASE3 · NCT05405166
- [Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)](https://clinicaltrials.gov/study/NCT05248646) — ACTIVE_NOT_RECRUITING · PHASE3 · NCT05248646

---

Source: AmericanPeptide.com — https://americanpeptide.com/catalog/pe-22-28
Data license: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Attribution: AmericanPeptide.com.
Research reference only — computational and educational content, not medical advice.